EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive: These data are in agreement with the finding that primary CML cells also exhibit increased phospho-eIF2α compared to healthy donors, with phospho-eIF2α substantially increasing in cells from patients at the advanced blast crisis stage of the disease [12].